This report provides all the information you require to better understand Johnson & Johnson 9 Janssen and its partnering interests and activities over the past seven years.

Johnson & Johnson / Janssen has also announced over 16 M&A deals since 2005, with the lead deals being the acquisition of Synthes, Crucell and Mentor

Johnson & Johnson, known as Janssen in Europe, announced over 176 partnering / licensing deals since 2005, with over 39 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in cardiovascular, cancer, infectives, central nervous system, genitourinary and metabolic diseases

Johnson & Johnson is a top pharma company active in partnering, licensing and M&A in biopharmaceuticals, medical devices and diagnostics

Janssen Biotech and Astellas, both top 50 pharma companies have entered into a pharma licensing agreement for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase inhibitor

Dealmaking activity rebounds to a year’s high

The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value

The start of 2012 has seen a significant surge in partnering announcements. In addition, the JP Morgan conference in San Francisco has resulted in a rash of announcements of partnering intentions for 2012

In little more than a few days at the start of January, Forma Therapeutics has announced another significant deal, this time with Janssen Biotech

Janssen Biotech has been busy in recent days, first announcing an $800 million partnership with Molecular Partners, and now signing another deal with Pharmacyclics

Janssen Biotech, a subsidiary of Johnson & Johnson, has secured a long term collaborative R&D deal with Molecular Partners for the development of novel multispecific DARPin products for up to four unmet need immunological disease targets

Ichor Medical Systems has entered into a product development collaboration and worldwide license agreement with Janssen Pharmaceuticals

Janssen Pharmaceuticals has acquired XO1 Limited

Vedanta Biosciences announced a license agreement with Janssen Biotech, for Vedanta’s lead microbiome pharmaceutical candidate (VE202)

AC Immune has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals

Vectura has entered into a global development and licence agreement with Janssen Biotech for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD

Isis Pharmaceuticals has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract

Janssen Biotech had inked a global collaboration and licensing agreement with MacroGenics

EB Pharma has executed an agreement with Janssen Pharmaceutica for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound

Janssen Biotech has inked a global collaboration and licensing agreement with MacroGenics.

Halozyme Therapeutics has entered into a worldwide Collaboration and License Agreement with Janssen Biotech for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme’s ENHANZE technology